

Hepatitis B Virus

**A Study of Pegylated Interferon Alfa-2A in Combination With Lamivudine or Entecavir Compared With Untreated Control Group in Children With Hepatitis B Envelope Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB) in the Immune-Tolerant Phase**

**Trial Status**  
Completed

**Trial Runs In**  
12 Countries

**Trial Identifier**  
NCT02263079 2006-000977-31  
NV25361

---

*The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.*

***Trial Summary:***

This randomized, controlled, parallel group, open-label multicenter study will evaluate the efficacy and safety of a combination of pegylated interferon alfa-2A (Pegasys) plus lamivudine or entecavir compared with an untreated control group in participants with HBeAg positive CHB in the immune tolerant phase. NOTE: STUDY RECRUITMENT HAS BEEN TERMINATED

**Hoffmann-La Roche**  
Sponsor

**Phase 3**  
Phase

---

**NCT02263079 2006-000977-31 NV25361**  
Trial Identifiers

---

***Eligibility Criteria:***

**Gender**  
All

**Age**  
>= 3 Years & <= 17 Years

**Healthy Volunteers**  
No

---